New shigella vaccine shows promise in first human trial
NCT ID NCT05073003
First seen Jan 04, 2026 · Last updated May 25, 2026 · Updated 24 times
Summary
This study tested a new vaccine designed to prevent diarrhea caused by Shigella bacteria, a major cause of illness in young children in Africa. The vaccine was first given to adults in Europe, then to adults, children, and infants in Africa to check safety and immune response. Researchers aimed to find the best dose for protecting infants, who are most at risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHOEA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Kericho, 20200, Kenya
Conditions
Explore the condition pages connected to this study.